Evidence map›Paper›PMID 37887244›Full record

ReviewAntibiotics (Basel, Switzerland)2023

Inorganic Nanoparticles: Tools to Emphasize the Janus Face of Amphotericin B.

Ariane Boudier, Nour Mammari, Emmanuel Lamouroux, Raphaël E Duval

Open access · goldAbstract readReview
In one paragraph

Review in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 65% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. FromACS omega · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ariane BoudierUniversité de Lorraine, CITHEFOR, F-54000 Nancy, France.ORCID 0000-0001-5975-3646
Nour MammariUniversité de Lorraine, CNRS, L2CM, F-54000 Nancy, France.ORCID 0000-0002-3075-110X
Emmanuel LamourouxUniversité de Lorraine, CNRS, L2CM, F-54000 Nancy, France.ORCID 0000-0002-5987-8040
Raphaël E DuvalUniversité de Lorraine, CNRS, L2CM, F-54000 Nancy, France.ORCID 0000-0003-4349-5595
Centre National de la Recherche Scientifique · FRCibles thérapeutiques, formulation et expertise préclinique du médicament

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amphotericin B is the oldest antifungal molecule which is still currently widely used in clinical practice, in particular for the treatment of invasive diseases, even though it is not devoid of side effects (particularly nephrotoxicity). Recently, its redox properties (i.e., both prooxidant and antioxidant) have been highlighted in the literature as mechanisms involved in both its activity and its toxicity. Interestingly, similar properties can be described for inorganic nanoparticles. In the first part of the present review, the redox properties of Amphotericin B and inorganic nanoparticles are discussed. Then, in the second part, inorganic nanoparticles as carriers of the drug are described. A special emphasis is given to their combined redox properties acting either as a prooxidant or as an antioxidant and their connection to the activity against pathogens (i.e., fungi, parasites, and yeasts) and to their toxicity. In a majority of the published studies, inorganic nanoparticles carrying Amphotericin B are described as having a synergistic activity directly related to the rupture of the redox homeostasis of the pathogen. Due to the unique properties of inorganic nanoparticles (e.g., magnetism, intrinsic anti-infectious properties, stimuli-triggered responses, etc.), these nanomaterials may represent a new generation of medicine that can synergistically enhance the antimicrobial properties of Amphotericin B.

Indexed as

Amphotericin Bantimicrobialinorganic nanomaterialsoxidative stressredox properties

Identifiers

PMID37887244
PMCPMC10604816
OpenAlexW4387653425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.